Related Experiment Video
Updated: Aug 3, 2025
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Disease-Modifying Therapy in Subacute Sclerosing Panencephalitis: An Area of Darkness
Divyani Garg1, Suvasini Sharma2
1Department of Neurology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Abstract:
Subacute sclerosing panencephalitis (SSPE) is a neurodegenerative disorder because of the persistence of mutated measles virus in the central nervous system. Till date, no curative therapy has been established for SSPE. Multiple drugs have been tried to modify the disease process but have shown mild to moderate benefit at best. It is also challenging to attribute the relative success of some strategies described in single case reports because of the known phenomenon of spontaneous improvement in 5% of patients with SSPE. Critical gaps in understanding the pathophysiological processes involved exist. Current therapies such as interferon alfa require invasive strategies for administration by the intraventricular or intrathecal route, with varying dosage regimens. Oral therapies such as isoprinosine and ribavirin are expensive and not readily available in resource-constrained settings. Most of the evidence so far favors the use of combinational regimens. In this viewpoint, we critically summarize the current evidence on disease-modifying strategies in the context of our region.
Insights
Subacute sclerosing panencephalitis (SSPE) lacks a cure, with current treatments offering limited benefits. This review examines disease-modifying strategies for SSPE, focusing on regional applicability and evidence gaps.
Area of Science:
- Neuroscience
- Virology
- Immunology
Background:
- Subacute sclerosing panencephalitis (SSPE) is a progressive neurodegenerative disease caused by persistent measles virus infection in the CNS.
- No definitive cure exists for SSPE, and current therapeutic options provide only marginal benefits.
- Understanding SSPE pathophysiology remains incomplete, complicating treatment development.
Purpose of the Study:
- To critically review existing disease-modifying therapeutic strategies for SSPE.
- To evaluate the efficacy and limitations of current and investigational SSPE treatments.
- To contextualize treatment options within regional accessibility and resource constraints.
Main Methods:
- Systematic review of published literature on SSPE treatment strategies.
- Analysis of evidence for various drug regimens, including interferon alfa, isoprinosine, and ribavirin.
- Consideration of administration routes (intraventricular, intrathecal, oral) and dosage regimens.
Main Results:
- Most reported therapies for SSPE show mild to moderate efficacy.
- Combinational treatment regimens are generally favored over monotherapy.
- Invasive administration routes (interferon alfa) and expensive oral agents (isoprinosine, ribavirin) present challenges.
- Spontaneous improvement in 5% of SSPE cases complicates outcome attribution.
Conclusions:
- Current disease-modifying strategies for SSPE are limited in efficacy and accessibility.
- Further research is needed to address pathophysiological gaps and develop more effective therapies.
- Regional availability and cost are critical factors in selecting SSPE treatments.
